C Partners Holding GmbH Trims Stake in Thermo Fisher Scientific Inc. $TMO

C Partners Holding GmbH lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.5% during the 4th quarter, HoldingsChannel reports. The firm owned 54,399 shares of the medical research company’s stock after selling 5,044 shares during the period. Thermo Fisher Scientific accounts for approximately 8.5% of C Partners Holding GmbH’s portfolio, making the stock its 6th largest position. C Partners Holding GmbH’s holdings in Thermo Fisher Scientific were worth $31,522,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of TMO. High Note Wealth LLC increased its position in Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares during the last quarter. Swiss RE Ltd. bought a new position in Thermo Fisher Scientific during the fourth quarter valued at $28,000. JPL Wealth Management LLC bought a new position in Thermo Fisher Scientific during the third quarter valued at $28,000. Beacon Financial Strategies CORP bought a new position in Thermo Fisher Scientific during the fourth quarter valued at $29,000. Finally, Olistico Wealth LLC bought a new position in Thermo Fisher Scientific during the fourth quarter valued at $29,000. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on TMO shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Royal Bank Of Canada set a $490.00 price objective on shares of Thermo Fisher Scientific and gave the company a “sector perform” rating in a research report on Thursday, May 14th. DZ Bank assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They set a “buy” rating and a $610.00 target price for the company. Finally, Piper Sandler assumed coverage on shares of Thermo Fisher Scientific in a research note on Thursday, June 11th. They set a “neutral” rating and a $510.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $608.95.

Insiders Place Their Bets

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Down 0.2%

NYSE:TMO opened at $472.73 on Wednesday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The company has a 50-day moving average of $478.34 and a 200 day moving average of $525.54. The firm has a market cap of $175.68 billion, a PE ratio of 25.99, a price-to-earnings-growth ratio of 2.10 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period in the prior year, the firm earned $5.15 earnings per share. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.